Concord Biotech Limited — Board Meeting, 08-08-2025: Outcome of Board Meeting

Concord Biotech's board approved the Q1 financial results. For the quarter ending June 30, 2025, consolidated revenue hit ₹203.99 Cr, with profit after tax at ₹44.06 Cr. Shareholders can look forward to a dividend of ₹10.70 per equity share for FY24-25, with September 3, 2025, as the record date. The company also recently acquired a 75% ownership stake in Stellon Biotech Inc., USA, through a small equity investment of USD 1,500.